CU23529A1 - Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune - Google Patents
Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmuneInfo
- Publication number
- CU23529A1 CU23529A1 CU20050043A CU20050043A CU23529A1 CU 23529 A1 CU23529 A1 CU 23529A1 CU 20050043 A CU20050043 A CU 20050043A CU 20050043 A CU20050043 A CU 20050043A CU 23529 A1 CU23529 A1 CU 23529A1
- Authority
- CU
- Cuba
- Prior art keywords
- nervous system
- central nervous
- neuroregeneration
- autoinmune
- ghrp
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 3
- 230000035771 neuroregeneration Effects 0.000 title abstract 2
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 title 1
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 title 1
- 208000016192 Demyelinating disease Diseases 0.000 abstract 1
- 206010012305 Demyelination Diseases 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 1
- 108010051696 Growth Hormone Proteins 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 239000000122 growth hormone Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención es dirigida a estimular la neuroregeneración del sistema nervioso central debido al dano autoinmune. En particular la combinación farmacéutica que comprende concentraciones terapéuticamente efectivas del Factor de Crecimiento Epidérmico y del Hexapéptido Secretagogo de la Hormona de Crecimiento Humana es administrada a un sujeto que sufre de los síntomas de Esclerosis Múltiple y Neuromielitis Óptica y corrige la desmielinización causada por células autoreactivas en el Sistema Nervioso Central.
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20050043A CU23529A1 (es) | 2005-03-02 | 2005-03-02 | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
| EP06705745A EP1870106B1 (en) | 2005-03-02 | 2006-02-24 | Combination of egf/ghrp-6 for neuroregeneration of central nervous system |
| KR1020077022024A KR101255200B1 (ko) | 2005-03-02 | 2006-02-24 | 자가면역 손상에 따른 중추 신경계의 신경 재생용ｅｇｆ/ｇｈｒｐ-6의 조합 |
| DE602006006903T DE602006006903D1 (de) | 2005-03-02 | 2006-02-24 | Kombination von egf/ghrp-6 für die neuroregeneration des zentralnervensystems |
| AT06705745T ATE431743T1 (de) | 2005-03-02 | 2006-02-24 | Kombination von egf/ghrp-6 für die neuroregeneration des zentralnervensystems |
| US11/885,330 US20100093616A1 (en) | 2005-03-02 | 2006-02-24 | Combination of EGF/GHRP-6 for Neurogeneration of Central Nervous System Following Autoimmune Damage |
| PCT/CU2006/000001 WO2006092106A2 (es) | 2005-03-02 | 2006-02-24 | Combinación de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al daño autoinmune. |
| PT06705745T PT1870106E (pt) | 2005-03-02 | 2006-02-24 | Combinação de egf/ghrp-6 para a neurorregeneração do sistema nervoso central |
| RU2007136280/15A RU2403913C2 (ru) | 2005-03-02 | 2006-02-24 | Комбинация egf/ghrp-6 для нейрорегенерации центральной нервной системы после аутоиммунного повреждения |
| ES06705745T ES2327562T3 (es) | 2005-03-02 | 2006-02-24 | Combinacion de egf/ghrp-6 para la neurorregeneracion del sistema nervioso central. |
| JP2007557312A JP5001180B2 (ja) | 2005-03-02 | 2006-02-24 | 自己免疫障害後の中枢神経系の神経再生に用いるｅｇｆ／ｇｈｒｐ−６の組合せ |
| BRPI0607844A BRPI0607844B8 (pt) | 2005-03-02 | 2006-02-24 | uso do egf e ghrp-6 |
| MYPI20060792A MY142494A (en) | 2005-03-02 | 2006-02-24 | Combination of egf/ghrp-6 for neuroregeneration of central nervous system following autoimmune damage |
| CN2006800139592A CN101180044B (zh) | 2005-03-02 | 2006-02-24 | 用于自身免疫损伤后中枢神经系统神经再生的egf/ghrp-6组合 |
| AU2006220154A AU2006220154B2 (en) | 2005-03-02 | 2006-02-24 | Combination of EGF/GHRP-6 for neurogeneration of central nervous system |
| CA2600628A CA2600628C (en) | 2005-03-02 | 2006-02-24 | Combination of egf/ghrp-6 for neurogeneration of central nervous system following autoimmune damage |
| MX2007010717A MX2007010717A (es) | 2005-03-02 | 2006-02-24 | Combinacion de egf/ghrp-6 para la neuroregeneracion del sistema nervioso central posterior al dano autoinmune. |
| ZA200707020A ZA200707020B (en) | 2005-03-02 | 2007-08-21 | Combination of EGF/GHRP-6 for neuroregeneration of central nervous system following autoimmune damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20050043A CU23529A1 (es) | 2005-03-02 | 2005-03-02 | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23529A1 true CU23529A1 (es) | 2010-06-17 |
Family
ID=40280698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20050043A CU23529A1 (es) | 2005-03-02 | 2005-03-02 | Combinación de egf/ghrp-6 para la neuroregeneración del sistema nervioso central posterior al dano autoinmune |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20100093616A1 (es) |
| EP (1) | EP1870106B1 (es) |
| JP (1) | JP5001180B2 (es) |
| KR (1) | KR101255200B1 (es) |
| CN (1) | CN101180044B (es) |
| AT (1) | ATE431743T1 (es) |
| AU (1) | AU2006220154B2 (es) |
| BR (1) | BRPI0607844B8 (es) |
| CA (1) | CA2600628C (es) |
| CU (1) | CU23529A1 (es) |
| DE (1) | DE602006006903D1 (es) |
| ES (1) | ES2327562T3 (es) |
| MX (1) | MX2007010717A (es) |
| MY (1) | MY142494A (es) |
| PT (1) | PT1870106E (es) |
| RU (1) | RU2403913C2 (es) |
| WO (1) | WO2006092106A2 (es) |
| ZA (1) | ZA200707020B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2644618B1 (en) | 2007-02-09 | 2016-08-17 | Ocera Therapeutics, Inc. | tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators |
| CU24591B1 (es) * | 2018-08-21 | 2022-04-07 | Ct Ingenieria Genetica Biotecnologia | Kit para la restauración del daño cerebral que comprende el factor de crecimiento epidérmico y el hexapéptido secretagogo de la hormona de crecimiento |
| ES2967696T3 (es) | 2019-04-08 | 2024-05-03 | Giuseppe Scalabrino | Factor de crecimiento epidérmico (EGF) y variantes del mismo para tratar o prevenir trastornos desmielinizantes inflamatorios |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9804064D0 (sv) * | 1998-11-25 | 1998-11-25 | A & Science Invest Ab | Medicinal product and method for treatment of conditions affecting neural stem cells or progenitor cells |
| CU23157A1 (es) * | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
| JP3993560B2 (ja) * | 2001-08-30 | 2007-10-17 | ステム セル セラピューティクス インコーポレイテッド | 神経幹細胞の分化およびその治療用途 |
| CU23043A1 (es) * | 2001-12-20 | 2005-05-20 | Ct Ingenieria Genetica Biotech | Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico. |
| EP1506997A1 (en) * | 2003-08-14 | 2005-02-16 | NeuroProgen GmbH Leipzig | Method of generating neural stem cells |
-
2005
- 2005-03-02 CU CU20050043A patent/CU23529A1/es active IP Right Grant
-
2006
- 2006-02-24 WO PCT/CU2006/000001 patent/WO2006092106A2/es not_active Ceased
- 2006-02-24 EP EP06705745A patent/EP1870106B1/en not_active Expired - Lifetime
- 2006-02-24 JP JP2007557312A patent/JP5001180B2/ja not_active Expired - Fee Related
- 2006-02-24 US US11/885,330 patent/US20100093616A1/en not_active Abandoned
- 2006-02-24 BR BRPI0607844A patent/BRPI0607844B8/pt not_active IP Right Cessation
- 2006-02-24 CN CN2006800139592A patent/CN101180044B/zh not_active Expired - Lifetime
- 2006-02-24 KR KR1020077022024A patent/KR101255200B1/ko not_active Expired - Fee Related
- 2006-02-24 PT PT06705745T patent/PT1870106E/pt unknown
- 2006-02-24 CA CA2600628A patent/CA2600628C/en not_active Expired - Fee Related
- 2006-02-24 MX MX2007010717A patent/MX2007010717A/es active IP Right Grant
- 2006-02-24 ES ES06705745T patent/ES2327562T3/es not_active Expired - Lifetime
- 2006-02-24 DE DE602006006903T patent/DE602006006903D1/de not_active Expired - Lifetime
- 2006-02-24 AT AT06705745T patent/ATE431743T1/de not_active IP Right Cessation
- 2006-02-24 AU AU2006220154A patent/AU2006220154B2/en not_active Ceased
- 2006-02-24 RU RU2007136280/15A patent/RU2403913C2/ru active
- 2006-02-24 MY MYPI20060792A patent/MY142494A/en unknown
-
2007
- 2007-08-21 ZA ZA200707020A patent/ZA200707020B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006006903D1 (de) | 2009-07-02 |
| JP5001180B2 (ja) | 2012-08-15 |
| MY142494A (en) | 2010-11-30 |
| CA2600628A1 (en) | 2006-09-08 |
| BRPI0607844A2 (pt) | 2010-10-19 |
| EP1870106B1 (en) | 2009-05-20 |
| EP1870106A2 (en) | 2007-12-26 |
| RU2007136280A (ru) | 2009-04-10 |
| AU2006220154A1 (en) | 2006-09-08 |
| MX2007010717A (es) | 2007-10-12 |
| WO2006092106A2 (es) | 2006-09-08 |
| BRPI0607844B8 (pt) | 2021-05-25 |
| PT1870106E (pt) | 2009-08-25 |
| CA2600628C (en) | 2013-04-09 |
| KR101255200B1 (ko) | 2013-04-23 |
| KR20070107790A (ko) | 2007-11-07 |
| CN101180044B (zh) | 2010-12-08 |
| RU2403913C2 (ru) | 2010-11-20 |
| JP2008531607A (ja) | 2008-08-14 |
| ATE431743T1 (de) | 2009-06-15 |
| US20100093616A1 (en) | 2010-04-15 |
| AU2006220154B2 (en) | 2010-05-27 |
| BRPI0607844B1 (pt) | 2018-08-28 |
| ES2327562T3 (es) | 2009-10-30 |
| ZA200707020B (en) | 2009-08-26 |
| WO2006092106A3 (es) | 2006-12-14 |
| CN101180044A (zh) | 2008-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2496892T3 (es) | Formulaciones para el tratamiento de trastornos del tracto respiratorio superior | |
| CO2021014694A2 (es) | Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio | |
| HN2006013804A (es) | Heteroalrilamidas[3.1.0]biciclicas como inhibidores del trasporte de glicina de tipo i | |
| MX391970B (es) | Interferon porcino pegilado y metodos de utilizacion del mismo. | |
| ECSP12011803A (es) | Polipéptidos inmunomoduladores derivados de la il-2 y su uso terapéutico en cáncer y en infecciones crónicas | |
| DE602005011753D1 (de) | Pharmazeutische zusammensetzungen mit midazolam in hoher konzentration | |
| CL2008001374A1 (es) | Compuestos derivados de pirazolo pirimidinas, inhibidores de pde9; composicion farmaceutica que comprende a dichos compuetos; utiles en el tratamiento de un trastorno neurodegenerativo y cognitivo tal como la enfermedad de alzheimer y esquizofrenia. | |
| BR112014009418A2 (pt) | macrociclos peptidomiméticos | |
| ECSP077281A (es) | Conjugados de hormona del crecimiento humana y polietilenglicol ramificado con glicerol, proceso para su preparación y métodos de uso de los mismos | |
| UY33222A (es) | Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas | |
| ECSP15008695A (es) | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa | |
| MX2011009323A (es) | Suplemento masticable organico. | |
| CL2008001560A1 (es) | Compuestos derivados de heterociclo de nitrogenado, moduladores de gamma secretasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas como el alzheimer, sindrome de down; kit farmaceutico. | |
| BRPI0721984B8 (pt) | interferon-2b peguilado (ifn-2b), seu método de preparo e de purificação, composição, bem como uso dos mesmos | |
| WO2014164285A3 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
| CL2021003474A1 (es) | Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria | |
| AR057239A1 (es) | Inmunoglobulinas | |
| ATE526012T1 (de) | Pharmazeutische formulierungen von meloxicam | |
| ZA200707020B (en) | Combination of EGF/GHRP-6 for neuroregeneration of central nervous system following autoimmune damage | |
| PY0115427A (es) | Benzofenonas y sulfonas como inhibidores de la captacion de glicina | |
| ECSP109871A (es) | Soluciones farmacéuticas orales que contienen telbivudina | |
| CO2024002715A2 (es) | Formulaciones de radiprodil | |
| Díaz Fernández et al. | Perfil de severidad lesional del trauma esquelético maxilofacial | |
| MX2015006997A (es) | Composicion farmaceutica. | |
| AR068608A1 (es) | Neramexano para el tratamiento de nistagmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant of patent |